Etanercept: A soluble TNF-α receptor in the treatment of psoriasis

Therapy

Volumn 4, Issue 5, 2007, Pages 665-672

  Boehncke, Wolf Henning ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Biologics; Etanercept; Psoriasis; Psoriatic arthritis; TNF

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AUTOANTIBODY; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; FUMARIC ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; PLACEBO; PSORALEN; RETINOID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ANGIONEUROTIC EDEMA; ANTIBODY PRODUCTION; AREA UNDER THE CURVE; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; DISEASE CONTROL; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG USE; ERYTHEMA; EVIDENCE BASED MEDICINE; HUMAN; INFECTION; INJECTION SITE REACTION; LONG TERM CARE; LOW DRUG DOSE; LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; PAIN; PHOTOTHERAPY; PRACTICE GUIDELINE; PRURITUS; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; SWELLING; SYMPTOM; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

EID: 35348873233     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/14750708.4.5.665     Document Type: Article

References (39)

1. Schön MP, Boehncke W-H: Psoriasis. N. Engl. J. Med. 352, 1899-1912 (2005).
2. Ferrandiz C, Pujol RM, Garcia-Patos V, Bordas X, Smandia J: Psoriasis of early and late nset: A clinical and epidemiologic study from Spain. J. Am. Acad. Dermatol. 46, 867-873 (2002).
3. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T: Psoriasis is common, carries a substantial burden even when not extensive. and is associated with widespread treating dissatisfaction. J. Invest. Dermatol. Symp. Proc. 9, 136-139 (2004),
4. Richards HL, Fortune DG, O'Sullivan TM, Main CJ, Griffiths CE: Patients with psoriasis and their complicance with medication. J. Am. Acad. Dermatol. 41, 581-583 (1999).
5. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM: Psoriasis causes as much disability as other major medical diseases. J. Am. Acad Dermatol. 41, 401-407 (1999).
6. Henseler T, Christophers E: Disease concomitance in psoriasis. J. Am. Acad Dermatol. 32, 982-986 (1995)
7. Ludwig RJ, Herzog C, Rostock A et al.: Psoriasis: a possible risk factor for development of coronary artery calcification. Br. J. Dermatol. 156, 271-276 (2007)
8. Gelfand J, Neimann AL, Shin DB et al.: Risk for myocardial infarction in patients with psoriasis. JAMA 296, 1735-1741 (2006).
9. Boehncke W-M, Prinz J, Gottlieb AB: Systematic review of biologic therapies for psoriasis. J. Rheumatol. 33, 1447-1451 (2006).
10. Strober BE, Siu K, Menon K: Systematic review of conventional systemic agents for psoriasis. J. Rheumatol 33, 1442-1446 (2006).
11. Sterry W, Barker J, Boehncke W-H et al.: Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br. J. Dermatol. 151(Suppl. 69), 3-17 (2004).
12. Boehncke W-H, Brasie JA, Barker J et al.: Treatment of psoriasis in Europe using etanercept: thoughts and recommendations from a Dermatology Expert Panel. J. Eur. Acad. Der. Venerol. 20, 988-998 (2006).
13. Strober BE: The treatment of psoriasis with etanercept. Semin. Cutan. Med. Surg. 24, 28-36 (2005).
14. Zhou H: Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J. Clin. Pharmacol. 45, 490-497 (2005).
15. Goldsmith DR, Wagstaff AJ: Etanercept: a review of its use in the managament of plaque psoriasis and psoriatic arthritis. Am. J. Clin. Dermatol. 6, 122-133 (2005).
16. Korth-Bradley JM, Rubin AS, Hanna RK, Simcoe DK, Lebsack ME: The pharmacokinetics of etanercept in healthy volunteers. Ann. Pharmacother. 34, 161-164 (2000).
17. Gottlieb AB, Chamian F, Masud S et al.: TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J. Immunol. 175, 2721-2729 (2005).
18. Lizzui P, Aphale A, Malaviya R et al.: Differential expression of phosphorylated NF-κB/Re1A in normal and psoriatic epidermis and downregulation of NF-κB in response to treatment with etanercept. J. Invest. Dermatol. 124, 1278-1283 (2005).
19. Malavixa R, Sun Y, Tan JK et al.: Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients. J. Am. Acad Dermatol. 55, 590-597 (2006).
20. Mease PJ, Goffe BS, Metz J, VanderStoep V, Finck B, Burge DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356, 385-390 (2000).
21. Mease PJ, Kivitz AJ, Burch FX et al.: Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 50 (7), 2264-2272 (2004).
22. Gottlieb AB, Matheson RT Lowe N et al.: A randomized trial of etanercept as monotherapy for psoriasis. Ach. Dermatol. 139, 1627-1632 (2003).
23. Leonardi CL, Powers JL, Matheson RT et al.: Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349, 2014-2022 (2003).
24. Papp K, Bissonnette R, Krueger JG et al.: The treatment of moderate to severe psoriasis with a new anti-CD11 a monoclonal antibody. J. Am. Acad. Dermatol. 45, 665-674 (2001).
25. Yamauchi PS, Gindi V, Lowe NJ: The treatment of psoriasis and psorlatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety. Dermatol. Clin. 22, 449-459 (2004).
26. Enbrel®, package insert. Immunex Corp., CA, USA.
27. Mohan AK, Coté TR, Block JA, Manadan AM, Siegel JN, Braun M: Tuberculosis following theuse of etanercept, a tumor necrosis factor inhibitor. Clin. Infect. Dis. 39, 295-299 (2004).
28. Gelfand JM, Berlin J Van Voorhees A, Margolis DJ: Lymphoma rates are low but Increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Ach. Dermatol. 139, 1425-1429 (2003).
29. Mohan N, Edwards ET, Cupps TR et al.: Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthrit. Rheum. 44, 2862-2869 (2001).
30. Shakoor N, Michalska M, Harris C, Block JA: Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359, 579-580 (2002).
31. Swale VJ, Perrett CM, Denton CP, Black CM, Rustin MHA: Etanercpet-induced systemic lupus erythematosus. Clin. Exp. Dermatol. 28, 604-607 (2003).
32. Anker S, Coats A: How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL, and ATTACH. Int. J. Cardiol. 86, 123-130 (2002).
33. Kwon H, Cote T, Cuffe M, Kramer J. Braun M: Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann. Int. Med. 138, 807-811 (2003).
34. Smith CH, Anstey AV, Barker JN et al.: British Association of Dermatology guidelines for the use of biological interventions in psoriasis 2005. Br. J. Dermatol. 163, 486-497 (2005).
35. Nast A, Kopp IB, Augustin M et al.: S3-Leittinie zur Theraple der Psoriasis vulgarts. J. Dtsch Dermatol. Ges. 4(Suppl. 2), S1-S126 (2006).
36. Nelles S, Daniel D, Stratmann L et al: Die Psoriasis-Krankheitskosten korrelieren mit der Schwere des klinischen Befundes und nicht mit der psychischen Krankheitslast. Pharmacoeconomics (2007) (In Press).
37. Heinen-Kammerer T, Daniel D, Stratmann L et al.: Cost-effectiveness of psoriasis therapy with etanercept in Germany. J. Dtsh Dermatol. Ges. 5(9), 762-768 (2007).
38. Wellen KE, Hotamisligil GS: Inflammation, stress, and diabetes. J. Clin. Invest. 115, 1111-1119 (2005)
39. Molta CT, Davis R: Etanercept. In: Biologics in geneial medicine. Boehncke WH, Radeke RR (Eds). Springer, Heidelberg, Germany (2007).